Canandaigua National Bank & Trust’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $313K | Buy |
+5,962
| New | +$315K | 0.03% | 268 |
|
|
2025
Q4 | $292K | Sell |
5,962
-131
| -2% | -$6.11K | 0.03% | 272 |
|
|
2025
Q3 | $263K | Buy |
6,093
+131
| +2% | +$5.12K | 0.02% | 287 |
|
|
2025
Q2 | $229K | Hold |
5,962
| – | – | 0.02% | 294 |
|
|
2025
Q1 | $231K | Sell |
5,962
-200
| -3% | -$7.32K | 0.02% | 289 |
|
|
2024
Q4 | $208K | Hold |
6,162
| – | – | 0.02% | 312 |
|
|
2024
Q3 | $252K | Hold |
6,162
| – | – | 0.02% | 294 |
|
|
2024
Q2 | $237K | Hold |
6,162
| – | – | 0.03% | 284 |
|
|
2024
Q1 | $264K | Buy |
+6,162
| New | +$254K | 0.04% | 234 |
|
|
2020
Q1 | $306K | Hold |
6,467
| – | – | 0.06% | 181 |
|
|
2019
Q4 | $380K | Hold |
6,467
| – | – | 0.06% | 189 |
|
|
2019
Q3 | $345K | Buy |
6,467
+1,794
| +38% | +$92.3K | 0.06% | 198 |
|
|
2019
Q2 | $234K | Hold |
4,673
| – | – | 0.04% | 240 |
|
|
2019
Q1 | $244K | Sell |
4,673
-1
| -0% | -$50 | 0.05% | 239 |
|
|
2018
Q4 | $223K | Hold |
4,674
| – | – | 0.05% | 249 |
|
|
2018
Q3 | $235K | Sell |
4,674
-609
| -12% | -$30.9K | 0.04% | 282 |
|
|
2018
Q2 | $266K | Buy |
5,283
+90
| +2% | +$4.53K | 0.05% | 255 |
|
|
2018
Q1 | $254K | Sell |
5,193
-7,045
| -58% | -$328K | 0.03% | 315 |
|
|
2017
Q4 | $543K | Buy |
12,238
+1,560
| +15% | +$72.1K | 0.1% | 160 |
|
|
2017
Q3 | $542K | Buy |
10,678
+6,195
| +138% | +$314K | 0.1% | 161 |
|
|
2017
Q2 | $242K | Hold |
4,483
| – | – | 0.05% | 217 |
|
|
2017
Q1 | $235K | Sell |
4,483
-165
| -4% | -$8.37K | 0.07% | 174 |
|
|
2016
Q4 | $223K | Sell |
4,648
-147
| -3% | -$7.26K | 0.07% | 176 |
|
|
2016
Q3 | $259K | Buy |
4,795
+180
| +4% | +$9.87K | 0.07% | 168 |
|
|
2016
Q2 | $250K | Hold |
4,615
| – | – | 0.07% | 167 |
|
|
2016
Q1 | $234K | Buy |
4,615
+280
| +6% | +$13.9K | 0.07% | 170 |
|
|
2015
Q4 | $219K | Sell |
4,335
-1,360
| -24% | -$69.3K | 0.07% | 182 |
|
|
2015
Q3 | $274K | Buy |
5,695
+317
| +6% | +$16.5K | 0.09% | 163 |
|
|
2015
Q2 | $280K | Buy |
5,378
+1,211
| +29% | +$68.2K | 0.08% | 169 |
|
|
2015
Q1 | $240K | Buy |
4,167
+382
| +10% | +$21.9K | 0.07% | 181 |
|
|
2014
Q4 | $202K | Buy |
3,785
+300
| +9% | +$16.8K | 0.06% | 188 |
|
|
2014
Q3 | $200K | Sell |
3,485
-264
| -7% | -$16.2K | 0.07% | 181 |
|
|
2014
Q2 | $251K | Sell |
3,749
-560
| -13% | -$37.9K | 0.08% | 160 |
|
|
2014
Q1 | $288K | Buy |
4,309
+8
| +0.2% | +$541 | 0.1% | 150 |
|
|
2013
Q4 | $287K | Buy |
+4,301
| New | +$279K | 0.1% | 142 |
|
Other funds holding GSK
JEST
MIP
EIC
MHI
DLA
Canandaigua National Bank & Trust's GSK Position: Q2 2026 in Review
Canandaigua National Bank & Trust opened a new position in GSK (GSK) in Q2 2026: 5,962 shares worth $313K. The stake represents 0.03% of the portfolio and ranks #268 among its holdings. This is a return to the name: Canandaigua National Bank & Trust previously reported a position in GSK as recently as Q4 2025.
Canandaigua National Bank & Trust first reported a position in GSK in Q4 2013 and has held it in 35 quarters since. The position peaked at $543K in Q4 2017. 627 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Canandaigua National Bank & Trust held 5,962 shares of GSK worth $313K as of Q2 2026.
- GSK was a new Canandaigua National Bank & Trust position in Q2 2026.
- GSK made up 0.03% of Canandaigua National Bank & Trust's portfolio in Q2 2026, its #268 holding.
- Canandaigua National Bank & Trust first reported a position in GSK in Q4 2013 and has held it in 35 quarters since.
- Canandaigua National Bank & Trust's GSK position peaked at $543K in Q4 2017.
- 627 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Canandaigua National Bank & Trust's 13F filing for Q2 2026, filed 7 Jul 2026.